Navigation Links
AstraZeneca and Mental Health Research Institute in Australia Announce Collaboration to Improve Early Detection of Alzheimer's Disease
Date:7/16/2009

LONDON, July 16 /PRNewswire-FirstCall/ -- AstraZeneca and The Mental Health Research Institute in Melbourne, Australia, today announced that they have entered into a research collaboration agreement to develop new ways of identifying Alzheimer's disease patients at early stages of the disease.

Researchers aim to find out whether testing cognition at short intervals (every one to three months) over an eighteen-month period will make it possible to identify individuals just at the point at which they are beginning to suffer cognitive decline as a result of Alzheimer's disease.

The study will be conducted in conjunction with The Australian Imaging, Biomarker & Lifestyle Flagship Study of Ageing (AIBL), which aims to improve understanding of the causes and diagnosis of Alzheimer's disease, and help develop preventative strategies.

Alzheimer's disease is a degenerative brain disease for which there is currently no definitive diagnostic tool. Doctors rely on their clinical judgment to diagnose the disease once it has become symptomatic, but the pathologic process very likely starts a few years beforehand.

Professor Paul Maruff, from the Mental Health Research Institute says, "When assessing cognitive function in an individual at risk for dementia on the first occasion, it is often difficult to determine whether their performance on cognitive tests has declined from some previously higher level. The repeated application of a set of brief and simple cognitive measures could therefore help to identify accurately the point when the onset of Alzheimer's disease was imminent in individual people. This could ultimately lead to a more personalized approach with more effective treatments being given to the right patients at the right time."

Dr Judith Jaeger, Director of Neuroscience Early Clinical Development at AstraZeneca adds, "We recognize that in addition to searching for new medicines, we urgently need to find new ways to identify those at risk of developing Alzheimer's disease before they begin to experience symptoms. In addition to developing a novel approach to diagnosing cognitive decline, we hope that our collaboration with the world-class researchers at The Mental Health Research Institute will provide insights that aid our search for new treatments and ways to prevent disease progression."

About AstraZeneca

AstraZeneca is a major international healthcare business engaged in the research, development, manufacturing and marketing of meaningful prescription medicines and supplier for healthcare services. AstraZeneca is one of the world's leading pharmaceutical companies with healthcare sales of US$ 31.6 billion and is a leader in gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infectious disease medicines. For more information about AstraZeneca, please visit: http://www.astrazeneca.com/

About AIBL

The Australian Imaging, Biomarker & Lifestyle Flagship Study of Ageing (AIBL) aims to improve understanding of the causes and diagnosis of Alzheimer's disease, and help develop preventative strategies. The study, consisting of a patient cohort of 1112 participants, will help researchers develop and confirm a set of diagnostic markers biomarkers and psychometrics that can be used to objectively monitor disease progression and to develop hypotheses about diet and lifestyle factors that might delay the onset of this disease. For more information, please visit: www.aibl.csiro.au

About MHRI

The Mental Health Research Institute (MHRI) located in Melbourne is Australia's premiere psychiatric research centre and is working to understand, detect, treat, and prevent mental illnesses. The Institute is formally affiliated with the University of Melbourne and Monash University.


'/>"/>
SOURCE AstraZeneca
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Abbott and AstraZeneca Extend Relationship to Include Co-Promotion of TRILIPIX(R) (fenofibric acid)
2. Abbott and AstraZeneca Submit New Drug Application to the FDA for CERTRIAD(TM), an Investigational Treatment for Mixed Dyslipidemia
3. AstraZeneca Studies Show Relief of Nighttime Heartburn and Reduction in GERD-Related Sleep Disturbances
4. Verus Pharmaceuticals Announces a Lawsuit Against AstraZeneca AB and Tika Lakemedel AB
5. Court Grants AstraZeneca Preliminary Injunction Against Apotex in PULMICORT RESPULES Patent Litigation
6. AstraZeneca, the National Alliance for Hispanic Health and LULAC Join Forces to Promote Needed Heart Health Education in Hispanic Communities
7. AstraZeneca Announces TOPROL-XL(R) (Metoprolol Succinate) is Now Available
8. Ingenuity Systems Announces Multi-Year Deal With AstraZeneca
9. Court Grants AstraZeneca Temporary Restraining Order Against Apotex in PULMICORT RESPULES Patent Litigation
10. FDA Advisory Committee Documents for SEROQUEL XR Available on AstraZeneca Web Site
11. AstraZenecas David Brennan Elected PhRMA Board Chairman
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... ... February 09, 2016 , ... Cirracore Enterprise ... enterprises move workloads to the cloud. Cirracore provides a secure VMware® vCloud ... traversing the Internet. Transformation Solutions (TSL Partners) provides a full range of ...
(Date:2/9/2016)... (PRWEB) , ... February 09, 2016 , ... ... specialty pharmacies, announces today the continuation of the ‘Pay It Forward’ program into ... prescription referral received at our specialty pharmacy. , “Since our Pay It ...
(Date:2/9/2016)... ... February 09, 2016 , ... On January 12, 2016 Paul ... appointment after they noticed their furnace not producing any heat. Shortly after entering the ... cracked heat exchanger was leaking dangerous levels of carbon monoxide into the home, at ...
(Date:2/9/2016)... ... February 09, 2016 , ... The ... Herberger’s and Younkers department stores, announced it has raised $176,000 to benefit the ... Holden Comprehensive Cancer Center at the University of Iowa, The Lynn Sage Cancer ...
(Date:2/9/2016)... ... 09, 2016 , ... ZipHearing.com is proud to ... hearing aids , increase industry transparency, and promote awareness of hearing solutions ... “For the average consumer, the hearing aid industry is esoteric and difficult to ...
Breaking Medicine News(10 mins):
(Date:2/9/2016)... -- Axovant Sciences Ltd. (NYSE:  AXON), a leading clinical-stage ... today announced further details of three new clinical ... of Lewy body dementia, a disease affecting approximately ... of the three studies were recently initiated and ... quarter. In addition, the Company reported financial results ...
(Date:2/9/2016)... The new report "Global Diagnostic Ultrasound Devices Market Assessment ... reveals that global diagnostic ultrasound devices market was valued at US$ ... million by 2019 at a CAGR of 6.8% from 2015 to ... has been analyzed for six geographies of North America ... , Latin America , Middle-East ...
(Date:2/9/2016)... 2016 The new report "Global Blood Monitoring & Cardiac Monitoring Devices ... Consulting group reveals that global market for blood monitoring & cardiac ... expected to grow to US$ 24,830.1 million by 2019 at a ... America , Europe , Asia-Pacific ... and Africa . The three major ...
Breaking Medicine Technology: